Friday - May 16, 2025
SAN RAMON, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO), will participate in KeyBanc’s Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2022. Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer, will represent the Company in a virtual session scheduled to begin at 1:30 PM ET.
The webcast will be available to investors and other interested parties by accessing the CooperCompanies’ website at http://investor.coopercos.com. A replay of the event will be available on the same webpage following its conclusion.
About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE: COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, CA, Cooper has a workforce of more than 14,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
ir@cooperco.com
Last Trade: | US$81.45 |
Daily Change: | 0.98 1.22 |
Daily Volume: | 2,531,773 |
Market Cap: | US$16.260B |
March 06, 2025 December 17, 2024 December 05, 2024 September 03, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load